Related Experiment Video
Updated: May 3, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
A longer acting rFVIII, safe and effective
1WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE.
In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.
In this issue of Blood, Mahlangu et al describe a well-designed and executed phase 3 multicenter study of a recombinant factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hemophilia A.
More Related Videos
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
06:48Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes
Published on: July 19, 2024
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
IV Infusion to Oral Dosing: Conversion Methods
Cardiopulmonary Resuscitation IV: Pharmacological Management
Venous Thrombosis III: Interprofessional Care
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions